Dalton Maag Launches Radically Simplified Font Licensing Model
2.3.2026 14:00:00 CET | Business Wire | Press release
Dalton Maag, the independent typeface design studio, today launched a comprehensive overhaul of its retail font licensing structure, consolidating complex rights into four licence types. The new model aims to eliminate ‘licence anxiety’ for creatives and businesses by replacing narrow, technical restrictions with broad, generous permissions.
For many years, the font industry has been defined by confusing bundling practices and legal traps. Whether a licence is too granular – forcing buyers to make too many small decisions – or too restrictive – blocking reasonable use – the result is the same: obstacles that hinder rather than enable creativity and communication. Dalton Maag’s new licensing structure directly addresses these challenges.
“We’ve seen font licensing become harder to understand and easier to get wrong,” said Lukas Paltram, Executive Creative Director at Dalton Maag. “Our goal was to make licensing as simple as it can be without sacrificing fairness. Designers should be able to focus on their work, not on interpreting edge cases.”
Richard Bailey, Operations Director, added: “We’ve replaced technicalities with four licence types based on practical actions. Organizations should only pay for the value they receive – measured by actual usage such as number of users, units, or page impressions – not unreasonable metrics like company size or revenue.”
A Streamlined Structure for Modern Needs
The new structure consolidates all retail uses into four broad categories, modernizing definitions to reflect the reality of content creation in 2026:
- Install & Use: Install fonts on devices to create documents, presentations, social media content, and artwork. This licence explicitly includes unattended devices, such as digital signage and interactive kiosks.
- Host & Link: Self-host webfonts and link them via CSS to your websites and online ads. This licence combines web and ad traffic into a single ‘page impressions’ metric, allowing organizations to benefit from volume discount tiers.
- Embed & Distribute: Embed fonts into distributed products, including eBooks, apps, games, and hardware. This allows projects to pivot between formats, such as from an eBook to an app, without needing to switch licence types.
- Unlimited: An all-inclusive licence, including all rights above plus software bundle distribution and server installation.
Commitment to Transparency
Under this new model, every new retail licence provides perpetual rights with no recurring fees. There are no hidden charges for using fonts in logo artwork and no ‘size traps’ based on employee count or revenue.
FontPass, In Parallel
The same approach applies to Dalton Maag’s font licensing subscription service, FontPass. Subscribers will see these clearer entitlements across the service, including the free tier for Creative Agencies, supporting a smoother path from concept to paid commercial output without licensing friction.
About Dalton Maag
Dalton Maag is a typeface design studio dedicated to designing typefaces that help brands communicate with the world. With an emphasis on transparency, simplicity, and collaboration, Dalton Maag offers a high-quality font library and custom font solutions for clients worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302445475/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom